<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
AMENDMENT TO APPLICATION OR REPORT
Filed pursuant to Section 12, 13, or 15(d) of THE
SECURITIES EXCHANGE ACT OF 1934
DEKALB Genetics Corporation
---------------------------
(Exact name of registrant as specified in charter)
AMENDMENT NO. 1
The undersigned registrant hereby amends the following items, financial
statements, exhibits or other portions of its Quarterly Report for the three
month period ended November 30, 1995 on form 10-Q as set forth in the pages
attached hereto:
Exhibit 27 - Financial Data Schedule
Exhibit 27 - Restated Financial Data Schedule for the three month period
ended November 30, 1994
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this amendment to be signed on its behalf by
the undersigned, thereunto duly authorized.
Date: February 21, 1996
<PAGE>
Item 6. Exhibits and Reports on Form 8-K Page
- ----------------------------------------- ----
(a) Exhibit 11 - Earnings Per Share Computation 12
Exhibit 27 - Financial Data Schedule
Exhibit 27 - Restated Financial Data Schedule
For the three month period ended November 30, 1994
(b) Reports on Form 8-K -
No Form 8-K was filed during the three months ended November 30, 1995.
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DEKALB Genetics Corporation
---------------------------
Date: February 21, 1996 Thomas R. Rauman
---------------------------------
(Signature)
Thomas R. Rauman
Vice President-Finance,
Chief Financial Officer
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Consolidated Statement of Operations and the Consolidated Balance Sheets and is
qualified in its entirety by reference to such financial statements.
</LEGEND>
<MULTIPLIER> 1000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> AUG-31-1996
<PERIOD-END> NOV-30-1995
<CASH> 4600
<SECURITIES> 0
<RECEIVABLES> 48500
<ALLOWANCES> 2700
<INVENTORY> 186300
<CURRENT-ASSETS> 263900
<PP&E> 245100
<DEPRECIATION> 141500
<TOTAL-ASSETS> 115500
<CURRENT-LIABILITIES> 188500
<BONDS> 0
0
0
<COMMON> 500
<OTHER-SE> 124500
<TOTAL-LIABILITY-AND-EQUITY> 415500
<SALES> 50100
<TOTAL-REVENUES> 50100
<CGS> 28400
<TOTAL-COSTS> 28400
<OTHER-EXPENSES> 19600
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 2300
<INCOME-PRETAX> (200)
<INCOME-TAX> (100)
<INCOME-CONTINUING> (100)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (100)
<EPS-PRIMARY> (.02)
<EPS-DILUTED> 0
</TABLE>
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Consolidated Statement of Operations and the Consolidated Balance Sheets and is
qualified in its entirety by reference to such financial statements.
</LEGEND>
<RESTATED>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> AUG-31-1995
<PERIOD-END> NOV-30-1994
<CASH> (500)
<SECURITIES> 0
<RECEIVABLES> 44400
<ALLOWANCES> 2000
<INVENTORY> 169000
<CURRENT-ASSETS> 241400
<PP&E> 233100
<DEPRECIATION> 136800
<TOTAL-ASSETS> 395100
<CURRENT-LIABILITIES> 174000
<BONDS> 0
0
0
<COMMON> 500
<OTHER-SE> 118900
<TOTAL-LIABILITY-AND-EQUITY> 395100
<SALES> 45200
<TOTAL-REVENUES> 45200
<CGS> 26900
<TOTAL-COSTS> 26900
<OTHER-EXPENSES> 17700
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 2100
<INCOME-PRETAX> (1500)
<INCOME-TAX> (600)
<INCOME-CONTINUING> (900)
<DISCONTINUED> (300)
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (1200)
<EPS-PRIMARY> (.23)
<EPS-DILUTED> 0
</TABLE>
